Scarica l'app Stockscreener
17.50
5.49%
0.91
Precedente Chiudi:
$16.59
Aprire:
$16.97
Volume 24 ore:
290.40K
Relative Volume:
0.65
Capitalizzazione di mercato:
$943.41M
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-13.62
EPS:
-1.2847
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
+12.90%
1M Prestazione:
+52.44%
6M Prestazione:
+144.41%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$16.62
$17.82
Intervallo di 1 settimana:
$15.05
$17.82
Portata 52W:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Confronta UPB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
17.50 | 894.36M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio Appoints Stacy Price as Chief Technology Officer - The Globe and Mail
Real time social sentiment graph for Upstream Bio Inc.Risk Adjusted Trade Signal Screening Tool - Newser
Upstream Bio Inc. stock retracement – recovery analysisFree Reliable Chart-Based Trade Entries - Newser
Comparing Upstream Bio Inc. in custom built stock radarsFree Short Term Buy Zone Stock Alerts - Newser
Real time breakdown of Upstream Bio Inc. stock performanceFree Chart Alert System With Entry Targets - Newser
Analyzing net buyer seller activity in Upstream Bio Inc.Free Conservative Long Term Growth Plans - Newser
What makes Upstream Bio Inc. stock price move sharplyForecasting Stock Moves with AI Insights - Newser
How Efficient Is Upstream Bio Inc. at Controlling Operating CostsChart Signal and Short-Term Forecast Tracker - Newser
Upstream Bio Inc. stock momentum explainedFree Investment Strategy With Predictable Gains - Newser
Tools to assess Upstream Bio Inc.’s risk profileFree Community Entry Consensus Trade Ideas - Newser
Building trade automation scripts for Upstream Bio Inc.Free Chart Breakout Buy Signal Detection - Newser
Tools to monitor Upstream Bio Inc. recovery probabilityHigh Reward Picks with Tight Risk Control - Newser
Q3 EPS Estimates for Upstream Bio Decreased by William Blair - Defense World
Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
How to manage a losing position in Upstream Bio Inc.Free Expert Verified Stock Trade Ideas - Newser
How to use a screener to detect Upstream Bio Inc. breakoutsFree Day Trading Signals With High Precision - Newser
Upstream Bio 2025 Q2 Earnings Net Loss Widens Despite Revenue Surge - AInvest
Upstream Bio, Inc. Reports Increased R&D Investments - TipRanks
Upstream Bio (UPB) Q2 R&D Soars 169% - The Globe and Mail
Is it too late to sell Upstream Bio Inc.Low Risk Strategy with Smart Entry Zones - Newser
Key resistance and support levels for Upstream Bio Inc.Free Swing Trade With Risk Management - Newser
Positive Outlook for Upstream Bio, Inc. Driven by Promising Clinical Trial Developments - TipRanks
Optimistic Buy Rating for Upstream Bio, Inc. Driven by Promising Lead Asset and Strong Execution - TipRanks
Upstream Bio's Q2 2025: Can a Robust Cash Position and TSLP Pipeline Sustain Investor Optimism Amid Rising Burn Rates? - AInvest
Upstream Bio Q2 Net Loss Narrows, Revenue Rises - MarketScreener
Upstream Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Upstream Bio's Strategic Momentum in TSLP Inhibition: A Pathway to Redefining Respiratory Disease Treatment? - AInvest
Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss - MarketScreener
Upstream Bio reports Q2 revenue $937k, consensus $317k - TipRanks
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewswire
Upstream Bio Advances 3 Phase 2 Trials for Novel Respiratory Drug, Q3 Data Readout Imminent - Stock Titan
When is Upstream Bio Inc. stock expected to show significant growthUnbelievable profit margins - Jammu Links News
What are analysts’ price targets for Upstream Bio Inc. in the next 12 monthsCapitalize on emerging investment opportunities - Jammu Links News
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):